Buclizine dihydrochloride

CAS: 129-74-8 F: C28H35Cl3N2 W: 505.95

Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat and shows anti-tumor activity[1][2][3].
Invitro	Buclizine (0.1-100 μM; 72 h) inhibits growth of MCF-7 cells[2].Buclizine (9.625-77 μM; 72 h) arrests the cell cycle in the G1 phase in a dose-dependent manner[2].Buclizine (0-75 μM; 72 h) decreases TCTP (translationally controlled tumor protein) and cell cycle regulatory proteins expression in MCF-7 cells, increases pro-apoptotic MCL-1S expression[2]. Cell Proliferation Assay[2]. Cell Line:
In Vivo	Buclizine dihydrochloride (30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation) shows potent teratogens in the rat[3]. Animal Model:
Name	Buclizine dihydrochloride
CAS	129-74-8
Formula	C28H35Cl3N2
Molar Mass	505.95
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Gamal A E Mostafa, et al. Buclizine. Profiles Drug Subst Excip Relat Methodol. 2011;36:1-33. [2]. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966 May 1;95(1):109-11. [3]. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget. 2016 Mar 29;7(13):16818-39.